MXPA99008669A - Antagonistas receptores c5a que no tienen sustancialmente actividad agonista. - Google Patents
Antagonistas receptores c5a que no tienen sustancialmente actividad agonista.Info
- Publication number
- MXPA99008669A MXPA99008669A MXPA99008669A MX9908669A MXPA99008669A MX PA99008669 A MXPA99008669 A MX PA99008669A MX PA99008669 A MXPA99008669 A MX PA99008669A MX 9908669 A MX9908669 A MX 9908669A MX PA99008669 A MXPA99008669 A MX PA99008669A
- Authority
- MX
- Mexico
- Prior art keywords
- analogues
- derivatives
- receptor antagonists
- agonist activity
- analogue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
Abstract
Se describen los polipeptidos analogos de la C5a humana que son antagonistas receptores de la C5a que no presentan sustancialmente analfilatoxina o actividad agonista, y los derivados de los analogos y las formas dimericas de los analogos o derivados. Tambien se proveen las moleculas de ADN que codifican a los polipeptidos y los metodos para hacer los analogos. Las formulaciones farmaceuticas que contienen un analogo de C5a, se usan terapeuticamente en el tratamiento de enfermedades mediadas por la C5a y condiciones inflamatorias en mamiferos, y como profilaxis para evitar o reducir la inflamacion causada por un incidente que causa inflamacion o que agrava una condicion inflamatoria existente, respectivamente. Ademas se describen los anticuerpos especificos para los analogos de la C5a, los derivados de los mismos, y los dimeros de los analogos y de los derivados que no presentan sustancialmente reactividad cruzada con la C5a humana. Los anticuerpos se usan para detectar o cuantificar el analogo o el derivado de la C5a en circulacion, asi como para modificar, por ejemplo, neutralizar, la actividad del antagonista receptor de la C5a en vivo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16259193A | 1993-12-06 | 1993-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99008669A true MXPA99008669A (es) | 2004-09-01 |
Family
ID=22586301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA99008669A MXPA99008669A (es) | 1993-12-06 | 1999-09-21 | Antagonistas receptores c5a que no tienen sustancialmente actividad agonista. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0733107A1 (es) |
JP (1) | JPH09506258A (es) |
CN (1) | CN1142854A (es) |
AU (1) | AU698919B2 (es) |
BR (1) | BR9408265A (es) |
CA (1) | CA2176825A1 (es) |
FI (1) | FI962319A0 (es) |
HU (1) | HUT75990A (es) |
IL (1) | IL111792A0 (es) |
MX (1) | MXPA99008669A (es) |
NO (1) | NO962348L (es) |
NZ (1) | NZ274917A (es) |
TW (1) | TW429262B (es) |
WO (1) | WO1995016033A1 (es) |
ZA (1) | ZA949647B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837499A (en) * | 1993-12-06 | 1998-11-17 | Ciba-Geigy Corporation | DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same |
JPH11507215A (ja) * | 1995-06-05 | 1999-06-29 | ノバルティス・アクチエンゲゼルシャフト | アゴニスト活性を実質的にもたないC5a受容体アンタゴニストおよび製造方法 |
WO1997022216A1 (en) * | 1995-12-13 | 1997-06-19 | Northern Telecom Limited | Integrated cellular voice and digital packet data telecommunications systems and methods for their operation |
AUPO755097A0 (en) * | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
TWI767415B (zh) * | 2020-11-18 | 2022-06-11 | 中國醫藥大學 | 自動化血液分析系統及自動化血液分析方法 |
CN113150106B (zh) * | 2021-04-26 | 2022-08-16 | 华中农业大学 | 来源于补体成分C5a的抗菌肽及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0305615A1 (en) * | 1987-09-03 | 1989-03-08 | Immunetech Pharmaceuticals, Inc. | Peptide antagonists for the C5a anaphylatoxin |
JP2703764B2 (ja) * | 1986-04-28 | 1998-01-26 | シータス オンコロジー コーポレイション | 補体成分C5aに対するモノクローナル抗体 |
-
1994
- 1994-11-16 HU HU9601538A patent/HUT75990A/hu unknown
- 1994-11-16 JP JP7516068A patent/JPH09506258A/ja active Pending
- 1994-11-16 BR BR9408265A patent/BR9408265A/pt not_active Application Discontinuation
- 1994-11-16 WO PCT/IB1994/000359 patent/WO1995016033A1/en not_active Application Discontinuation
- 1994-11-16 CN CN94194914A patent/CN1142854A/zh active Pending
- 1994-11-16 CA CA002176825A patent/CA2176825A1/en not_active Abandoned
- 1994-11-16 AU AU80025/94A patent/AU698919B2/en not_active Ceased
- 1994-11-16 EP EP94931155A patent/EP0733107A1/en not_active Withdrawn
- 1994-11-16 NZ NZ274917A patent/NZ274917A/en unknown
- 1994-11-28 IL IL11179294A patent/IL111792A0/xx unknown
- 1994-12-05 ZA ZA949647A patent/ZA949647B/xx unknown
- 1994-12-13 TW TW083111578A patent/TW429262B/zh not_active IP Right Cessation
-
1996
- 1996-06-03 FI FI962319A patent/FI962319A0/fi unknown
- 1996-06-05 NO NO962348A patent/NO962348L/no not_active Application Discontinuation
-
1999
- 1999-09-21 MX MXPA99008669A patent/MXPA99008669A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU698919B2 (en) | 1998-11-12 |
CA2176825A1 (en) | 1995-06-15 |
FI962319A (fi) | 1996-06-03 |
BR9408265A (pt) | 1996-12-10 |
NO962348D0 (no) | 1996-06-05 |
HU9601538D0 (en) | 1996-07-29 |
JPH09506258A (ja) | 1997-06-24 |
AU8002594A (en) | 1995-06-27 |
NZ274917A (en) | 1998-03-25 |
WO1995016033A1 (en) | 1995-06-15 |
FI962319A0 (fi) | 1996-06-03 |
NO962348L (no) | 1996-08-05 |
ZA949647B (en) | 1995-06-06 |
CN1142854A (zh) | 1997-02-12 |
IL111792A0 (en) | 1995-01-24 |
EP0733107A1 (en) | 1996-09-25 |
HUT75990A (en) | 1997-05-28 |
TW429262B (en) | 2001-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ravizza et al. | Inactivation of caspase‐1 in rodent brain: a novel anticonvulsive strategy | |
Konno et al. | Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus | |
UA27776C2 (uk) | Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців | |
FI891226A (fi) | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. | |
FI963101A (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut | |
DE69435171D1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
NO951613L (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
NO974258L (no) | IL-17-reseptor | |
Parente et al. | Relationship between the anti-phospholipase and anti-inflammatory effects of glucocorticoid-induced proteins | |
UA41879C2 (uk) | Засіб для лікування мотонейронових захворювань | |
SE9503924D0 (sv) | Novel opioid peptides | |
ATE258444T1 (de) | Therapeutische chemokine rezeptor antagonisten | |
GEP20074267B (en) | Receptor nucleic acids and polypeptides | |
FI960727A0 (fi) | Neurokiniiniantagonisteina käyttökelpoiset heterosyklit | |
DK1588706T3 (da) | Valsartantablet | |
DK0669979T3 (da) | C-C CKR-1, kemokinreceptor | |
ATE175347T1 (de) | Verwendung eines serotoninagonisten in kombination mit einem tachykininrezeptorantagonisten zur herstellung eines arzneimittels zur prävention oder behandlung der migräne | |
TW429262B (en) | C5a receptor antagonists having substantially no agonist activity | |
Dourish et al. | Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat | |
KR980002066A (ko) | 변이형 인간 성장호르몬 및 그의 용도 | |
Furuzawa-Carballeda et al. | Polymerized-Type I Collagen Induces Upregulation of Foxp3-Expressing CD4 Regulatory T Cells and Downregulation of IL-17-Producing CD4 T Cells (Th17) Cells in Collagen-Induced Arthritis | |
WO2001017558A3 (en) | Novel uses of mammalian ccr6 receptors and related reagents | |
Bechtold et al. | Appetite-modifying actions of pro-neuromedin U-derived peptides | |
Galle et al. | Knocking out IL‐6 by vaccination | |
ATE277639T1 (de) | Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten |